Smoking, lung function, and alpha 1-antitrypsin deficiency.

BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax (1997) 9.69

Genomewide linkage analysis of quantitative spirometric phenotypes in severe early-onset chronic obstructive pulmonary disease. Am J Hum Genet (2002) 2.23

Liver injury in alpha1-antitrypsin deficiency: an aggregated protein induces mitochondrial injury. J Clin Invest (2002) 1.84

Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ (1997) 1.66

alpha 1-Antitrypsin: molecular pathology, leukocytes, and tissue damage. J Clin Invest (1986) 1.61

Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax (2004) 1.55

Molecular biomarkers for quantitative and discrete COPD phenotypes. Am J Respir Cell Mol Biol (2008) 1.51

Multifactorial analysis of family data ascertained through truncation: a comparative evaluation of two methods of statistical inference. Am J Hum Genet (1988) 1.47

Structure of human neutrophil elastase in complex with a peptide chloromethyl ketone inhibitor at 1.84-A resolution. Proc Natl Acad Sci U S A (1989) 1.46

Emphysema associated with complete absence of alpha 1- antitrypsin in serum and the homozygous inheritance [corrected] of a stop codon in an alpha 1-antitrypsin-coding exon. Am J Hum Genet (1988) 1.37

Chronic obstructive pulmonary disease. 1: Susceptibility factors for COPD the genotype-environment interaction. Thorax (2002) 1.31

Alpha1-antitrypsin deficiency. 4: Molecular pathophysiology. Thorax (2004) 1.18

Genetics and respiratory disease. 2. Alpha 1-antitrypsin deficiency, cirrhosis and emphysema. Thorax (1998) 1.17

Alpha-1 antitrypsin deficiency is not a rare disease but a disease that is rarely diagnosed. Environ Health Perspect (2003) 1.15

Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history. Thorax (2004) 1.15

Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. Thorax (2007) 1.12

Systematic review of the evidence relating FEV1 decline to giving up smoking. BMC Med (2010) 1.11

Circulating monocytes from healthy individuals and COPD patients. Respir Res (2003) 1.07

Prenatal diagnosis of alpha 1 antitrypsin deficiency and estimates of fetal risk for disease. J Med Genet (1987) 1.07

Mysteries of α1-antitrypsin deficiency: emerging therapeutic strategies for a challenging disease. Dis Model Mech (2014) 1.02

Alpha-1-antitrypsin deficiency: current concepts. Lung (2007) 1.00

Peripheral blood gene expression profiles in COPD subjects. J Clin Bioinforma (2011) 0.99

Signaling networks controlling mucin production in response to Gram-positive and Gram-negative bacteria. Glycoconj J (2001) 0.98

α₁-Antitrypsin modulates lung endothelial cell inflammatory responses to TNF-α. Am J Respir Cell Mol Biol (2013) 0.98

Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease. Am J Public Health (1991) 0.98

The role of collagenase in emphysema. Respir Res (2001) 0.96

The endosomal protein-sorting receptor sortilin has a role in trafficking α-1 antitrypsin. Genetics (2012) 0.95

Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis. Drug Des Devel Ther (2011) 0.92

Genetics and lung disease. BMJ (1991) 0.91

Cigarette smoke-induced pulmonary inflammatory responses are mediated by EGR-1/GGPPS/MAPK signaling. Am J Pathol (2010) 0.89

Alpha 1-antitrypsin deficiency--diagnosis, treatment, and control: identification of patients. Lung (1990) 0.89

Genes and chronic obstructive pulmonary disease. Med Clin North Am (2012) 0.88

Clinical features and prognosis of life time non-smokers with severe alpha 1-antitrypsin deficiency. Thorax (1998) 0.87

Risk factors for symptom onset in PI*Z alpha-1 antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis (2006) 0.86

Decline in pulmonary function in patients with alpha 1-antitrypsin deficiency. Lung (1990) 0.86

Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank. Int J Chron Obstruct Pulmon Dis (2009) 0.84

Protein misfolding and the serpinopathies. Prion (2007) 0.83

Alpha-1 antitrypsin deficiency. Arch Dis Child (2001) 0.81

[Alpha1-antitrypsin deficiency in Austria: analysis of the Austrian Alpha1-international-registry database]. Wien Klin Wochenschr (2010) 0.81

A genome-wide RNAi screen identifies potential drug targets in a C. elegans model of α1-antitrypsin deficiency. Hum Mol Genet (2014) 0.81

Glutathione S-transferase and microsomal epoxide hydrolase gene polymorphisms and risk of chronic obstructive pulmonary disease in Slovak population. Croat Med J (2008) 0.81

Novel treatment strategies for liver disease due to α1-antitrypsin deficiency. Clin Transl Sci (2012) 0.81

SERPINA1 PiZ and PiS heterozygotes and lung function decline in the SAPALDIA cohort. PLoS One (2012) 0.81

The association of down-regulated toll-like receptor 4 expression with airflow limitation and emphysema in smokers. Respir Res (2012) 0.80

Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes. Ther Clin Risk Manag (2015) 0.78

Whole exome sequencing identifies novel candidate genes that modify chronic obstructive pulmonary disease susceptibility. Hum Genomics (2016) 0.78

GGPPS, a new EGR-1 target gene, reactivates ERK 1/2 signaling through increasing Ras prenylation. Am J Pathol (2011) 0.78

Disorders of protein misfolding: alpha-1-antitrypsin deficiency as prototype. J Pediatr (2013) 0.77

A large scale gene-centric association study of lung function in newly-hired female cotton textile workers with endotoxin exposure. PLoS One (2013) 0.76

α1-antitrypsin Deficiency: A Misfolded Secretory Protein Variant with Unique Effects on the Endoplasmic Reticulum. Endoplasmic Reticulum Stress Dis (2016) 0.75

Decreased specific anti-elastase activity in the uninvolved skin of patients with psoriasis. Arch Dermatol Res (1991) 0.75

Three cases of alpha-1-antitrypsin deficiency in the elderly. Postgrad Med J (1991) 0.75

Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients. Respir Res (2017) 0.75

The epidemiology of alpha 1-antitrypsin deficiency. Lung (1990) 0.75

Alpha(1)-Antitrypsin Deficiency. Curr Treat Options Gastroenterol (2000) 0.75

The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature (1992) 5.71

The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem (2001) 4.81

Structure and variation of human alpha 1-antitrypsin. Nature (1982) 4.13

Structure of a serpin-protease complex shows inhibition by deformation. Nature (2000) 4.02

Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry (1989) 3.18

The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci U S A (1997) 3.09

The estimation of red cell superoxide dismutase activity. J Lab Clin Med (1975) 2.75

Mutation of antitrypsin to antithrombin. alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder. N Engl J Med (1983) 2.36

What do dysfunctional serpins tell us about molecular mobility and disease? Nat Struct Biol (1995) 2.30

Variations in the structure of human haemoglobin. With particular reference to the unstable haemoglobins. Br Med Bull (1969) 2.07

Social class, coronary risk factors and undernutrition, a double burden of diseases, in women during transition, in five Indian cities. Int J Cardiol (1999) 2.04

Familial dementia caused by polymerization of mutant neuroserpin. Nature (1999) 1.88

A simple method for the detection of unstable haemoglobins. Br J Haematol (1972) 1.87

The modernization of Asia. Implications for coronary heart disease. Council on Arteriosclerosis of the International Society and Federation of Cardiology. Circulation (1996) 1.76

Reactions involving superoxide and normal and unstable haemoglobins. Biochem J (1976) 1.66

Inhibitory conformation of the reactive loop of alpha 1-antitrypsin. Nat Struct Biol (1996) 1.66

BMI compared with central obesity indicators in relation to diabetes and hypertension in Asians. Obesity (Silver Spring) (2008) 1.64

alpha 1-Antitrypsin: molecular pathology, leukocytes, and tissue damage. J Clin Invest (1986) 1.61

Prevalence of coronary artery disease and coronary risk factors in rural and urban populations of north India. Eur Heart J (1997) 1.61

Elevated serum lipoprotein(a) in subclinical hypothyroidism. Clin Endocrinol (Oxf) (1995) 1.61

Kinetic bases of the primary hyperlipidaemias: studies of apolipoprotein B turnover in genetically defined subjects. Eur J Clin Invest (1980) 1.55

Inactive conformation of the serpin alpha(1)-antichymotrypsin indicates two-stage insertion of the reactive loop: implications for inhibitory function and conformational disease. Proc Natl Acad Sci U S A (2000) 1.54

Association between simple anthropometric indices and cardiovascular risk factors. Int J Obes Relat Metab Disord (2001) 1.52

A circulating variant of human proalbumin. Nature (1978) 1.52

Crystal structure of uncleaved ovalbumin at 1.95 A resolution. J Mol Biol (1991) 1.52

Kinetic characterisation of alpha-1-antitrypsin F as an inhibitor of human neutrophil elastase. Pathology (1996) 1.49

Effect of the Z mutation on the physical and inhibitory properties of alpha 1-antitrypsin. Biochemistry (1993) 1.49

Homozygous Tangier disease and cardiovascular disease. Atherosclerosis (1994) 1.48

Hormone binding globulins undergo serpin conformational change in inflammation. Nature (1988) 1.47

Abnormal haem binding and globin SH group blockade in unstable haemoglobins. Nature (1968) 1.44

Plakalbumin, alpha 1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis. Nature (1985) 1.44

Crystal structure of ovalbumin as a model for the reactive centre of serpins. Nature (1990) 1.42

Alpha 1-antitrypsin Siiyama (Ser53-->Phe). Further evidence for intracellular loop-sheet polymerization. J Biol Chem (1993) 1.41

Activated oxygen and haemolysis. Br J Haematol (1975) 1.41

A new hemoglobin variant resembling hemoglobin E. Hemoglobin E Saskatoon: beta-22 Glu replaced by Lys. Can J Biochem (1967) 1.40

The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure (1999) 1.40

Studies of hemoglobin denaturation and Heinz body formation in the unstable hemoglobins. J Clin Invest (1974) 1.39

Imprisonment of J-P Allain. Lancet (1993) 1.34

Haemoglobin Köln (beta-98 valine--methionine): an unstable protein causing inclusion-body anaemia. Nature (1966) 1.33

alpha 1-Antitrypsin Mmalton (Phe52-deleted) forms loop-sheet polymers in vivo. Evidence for the C sheet mechanism of polymerization. J Biol Chem (1995) 1.33

Differences between alpha- and beta-chain mutants of human haemoglobin and between alpha- and beta-thalassaemia. Possible duplication of the alpha-chain gene. Br Med J (1968) 1.33

Quantitative studies of very low density lipoprotein: conversion to low density lipoprotein in normal controls and primary hyperlipidaemic states and the role of direct secretion of low density lipoprotein in heterozygous familial hypercholesterolaemia. Eur J Clin Invest (1980) 1.32

Effects of mutations in the hinge region of serpins. Biochemistry (1993) 1.29

The unstable haemoglobin haemolytic anaemias. Semin Hematol (1969) 1.27

The 2.6 A structure of antithrombin indicates a conformational change at the heparin binding site. J Mol Biol (1997) 1.27

A 2.6 A structure of a serpin polymer and implications for conformational disease. J Mol Biol (1999) 1.26

Structural and functional characterization of the abnormal Z alpha 1-antitrypsin isolated from human liver. FEBS Lett (1984) 1.24

Oxidation of human haemoglobin by copper. Mechanism and suggested role of the thiol group of residue beta-93. Biochem J (1977) 1.22

The serpin inhibitory mechanism is critically dependent on the length of the reactive center loop. J Biol Chem (2001) 1.22

The significance of monoclonal gammopathy in a normal population. Aust N Z J Med (1971) 1.16

Basis of the defect in alpha-1-antitrypsin deficiency. Nature (1973) 1.16

Preparation and characterization of latent alpha 1-antitrypsin. J Biol Chem (1995) 1.15

Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn-->Asp) J Clin Invest (1994) 1.14

Vesicoureteric reflux: segregation analysis. Am J Med Genet (1985) 1.14

Prevalence of antithrombin deficiency in the healthy population. Br J Haematol (1994) 1.13

Yeast KEX2 protease has the properties of a human proalbumin converting enzyme. Science (1987) 1.13

A new doubly substituted sickling haemoglobin: HbS-Oman. Br J Haematol (1989) 1.12

Conformational changes in serpins: II. The mechanism of activation of antithrombin by heparin. J Mol Biol (2000) 1.12

The amino acid sequence of the alpha chain of the major haemoglobin of the rat (Rattus norvegicus). Biochem J (1975) 1.11

alpha 1-Antitrypsin microheterogeneity. Isolation and physiological significance of isoforms. Biochim Biophys Acta (1982) 1.10

Social class and coronary disease in rural population of north India. The Indian Social Class and Heart Survey. Eur Heart J (1997) 1.07

Milk and blood alcohol. N Z Med J (1972) 1.07

Mechanism of oxyhaemoglobin breakdown on reaction with acetylphenylhydrazine. Biochem J (1978) 1.06

Dysfunctional C1-inhibitor(At), isolated from a type II hereditary-angio-oedema plasma, contains a P1 'reactive centre' (Arg444----His) mutation. Biochem J (1988) 1.06

Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia (1995) 1.06

Inhibition of plasmin, urokinase, tissue plasminogen activator, and C1S by a myxoma virus serine proteinase inhibitor. J Biol Chem (1993) 1.06

Polymorphisms of the gene encoding adiponectin and glycaemic outcome of Chinese subjects with impaired glucose tolerance: a 5-year follow-up study. Diabetologia (2006) 1.06

Alpha-1-antitrypsin-Pittsburgh. A potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf. J Clin Invest (1986) 1.05

Structural explanation for the deficiency of S alpha 1-antitrypsin. Nat Struct Biol (1996) 1.04

Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation. Blood (1998) 1.04

Implications for function and therapy of a 2.9 A structure of binary-complexed antithrombin. J Mol Biol (1998) 1.03

Importance of the release of strand 1C to the polymerization mechanism of inhibitory serpins. Protein Sci (1997) 1.03

The conformational activation of antithrombin. A 2.85-A structure of a fluorescein derivative reveals an electrostatic link between the hinge and heparin binding regions. J Biol Chem (2000) 1.03

Human alpha 1-antitrypsin: carbohydrate attachment and sequence homology. FEBS Lett (1981) 1.02

Drug overdoses: Is one stomach washing enough? N Z Med J (1975) 1.01

Conformational changes in serpins: I. The native and cleaved conformations of alpha(1)-antitrypsin. J Mol Biol (2000) 1.00

Polymerization of plasminogen activator inhibitor-1. J Biol Chem (2000) 1.00

Heparin-dependent modification of the reactive center arginine of antithrombin and consequent increase in heparin binding affinity. J Biol Chem (1997) 1.00

Functional abnormality of proalbumin Christchurch. Biochim Biophys Acta (1980) 1.00

Latent antithrombin and its detection, formation and turnover in the circulation. J Thromb Haemost (2004) 1.00

Is a single definition of the metabolic syndrome appropriate?--A comparative study of the USA and Asia. Atherosclerosis (2005) 1.00

Hydrolink gels: a rapid and simple approach to the detection of DNA mutations in thromboembolic disease. J Clin Pathol (1992) 1.00

Frequency distributions of apolipoprotein(a) kringle IV repeat alleles and their effects on lipoprotein(a) levels in Caucasian, Asian, and African populations: the distribution of null alleles is non-random. Eur J Hum Genet (1996) 1.00

The structural basis for neutrophil inactivation of C1 inhibitor. Biochem J (1989) 0.99

A genetically engineered mutant of alpha 1-antitrypsin protects connective tissue from neutrophil damage and may be useful in lung disease. Lancet (1984) 0.98

Haemoglobin sydney: Beta-67 (E11) valine modified to alanine: an emerging pattern of unstable haemoglobins. Nature (1967) 0.98

Plasma apolipoprotein (a) is increased in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia (1992) 0.98

Increased proteolytic cleavage of alpha 1-antitrypsin (alpha 1-proteinase inhibitor) in knee-joint synovial fluid from patients with rheumatoid arthritis. Biochem Soc Trans (1990) 0.98

Ovalbumin and angiotensinogen lack serpin S-R conformational change. Biochem J (1989) 0.98

The control of neutrophil chemotaxis by inhibitors of cathepsin G and chymotrypsin. J Biol Chem (1995) 0.98

Heparin binding defect in a new antithrombin III variant: Rouen, 47 Arg to His. Blood (1987) 0.97

Dietary intake and practices in the Hong Kong Chinese population. J Epidemiol Community Health (1998) 0.97

Blood lead levels in the New Zealand population: preliminary communication. N Z Med J (1984) 0.97

Formation of the antithrombin heterodimer in vivo and the onset of thrombosis. Blood (1999) 0.97

Influence of educational level and marital status on dietary intake, obesity and other cardiovascular risk factors in a Hong Kong Chinese population. Eur J Clin Nutr (1999) 0.96

Genetic variation in human apolipoprotein E. J Lipid Res (1982) 0.96

Probing serpin reactive-loop conformations by proteolytic cleavage. Biochem J (1996) 0.95

Protein C deficiency and portal thrombosis in liver transplantation in children. Lancet (1988) 0.95

Haemoglobin Genova: beta-28 (B10) leucine replaced by proline. Nature (1967) 0.95

Mutations which impede loop/sheet polymerization enhance the secretion of human alpha 1-antitrypsin deficiency variants. J Biol Chem (1995) 0.95